GlaxoSmithKline (GSK) shares moved higher on Friday after ViiV Healthcare, the HIV-focused business jointly owned with Pfizer, took a step forward in the marketing authorisation process for its Triumeq treatment.Based on two studies, the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended the authorisation of marketing of Triumeq, which is currently not approved in any country. The recommendation is one of the final steps before marketing authorisation is granted by the European Commission, the final decision of which is expected during the third quarter of this year. Triumeq is a once-daily dolutegravir-based tablet, for which a new drug application was submitted in the US in October last year. The regulatory submission and review processes have also been initiated in Canada, Australia, Brazil and Japan. "Today's positive opinion takes us a step closer to bringing physicians and people living with HIV a dolutegravir based regimen that can be taken once-daily as a single-tablet," said Dr. John Pottage, Chief Scientific and Medical Officer of ViiV Healthcare. "This opinion supports the potential of dolutegravir-based regimens, as well as the importance of our ongoing research into additional single-tablet treatment options." The share price had climbed 0.5% to 1,570.25p. NR